Biomarkers
A31 – A70
- A31: The Folliculin (FLCN) mutation database: an online resource for FLCN sequence variants involved in Birt-Hogg-Dube syndrome
- A32: Early detection of brain metastasis using novel MRI contrast agent targeting VCAM-1
- A33: Effects of lapatinib on the metabolic profile of NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice measured by in vitro 1H and 31P magnetic resonance spectroscopy
- A34: Identification of a biomarker of DNA repair deficiency via expression profiling of BRCA1 and BRCA2 deficient human tumours and cell-lines using a breast specific platform
- A35: CD8+ T cell function in cancer patients receiving chemotherapy
- A36: Proteomic dissection of an early colon cancer model: HMGB1 a potential biomarker
- A37: Is there a role for hepcidin in human cancers?
- A38: Evaluation of techniques for the analysis of KRAS mutation status in formalin fixed tissue
- A39: The effects of vandetanib on calcitonin (CTN) mRNA levels in cultured TT human medullary thyroid carcinoma cells
- A40: EN2 is a highly predictive and specific urine based biomarker for prostate cancer
- A41: From genome-wide association studies to clinical application: MSMB as a prostate cancer biomarker
- A42: Abstract withdrawn
- A43: Analysis of circulating tumour cells in prostate cancer patients for predictors of therapeutic response and prognosis
- A44: Building robust pharmacodynamic biomarker assays for phase I clinical trials
- A45: Tumour tissue profiling for biomarker discovery and validation at the drug targeting level: kinase activity
- A46: Developments in imaging hypoxia: new tracers and data modelling
- A47: Can plasma proteomic markers of response to chemotherapy in oesophageal cancer xenografts be applied clinically?
- A48: GIST mutation analysis in from EUS FNA cytology material: correlation with resected tumours in 10 cases
- A49: Foetal leukocytic DNA damage biomarkers as signatures of in utero genotoxicity: influence of maternal diet and lifestyle?
- A50: A method for quantifying the kinetics of hypoxia tracers using multicellular tumour spheroids
- A51: Multiplex analysis of Akt/mTOR and JAK/STAT signaling pathways
- A52: Development of MULTI-ARRAY® and MULTI-SPOT® immunoassays for cell cycle targets
- A53: In 100 sequences associated with alternatively spliced forms of estrogen receptor alpha in breast cancer
- A54: The role of Histone Deacetylase 4 (HDAC4) and its involvements in cisplatin resistant ovarian cancer
- A55: DNA ploidy as a prognostic biomarker after ALA photodynamic therapy for high grade dysplasia in Barrett’s oesophagus
- A56: Merkel cell polyomavirus in Merkel cell carcinoma: pilot project to develop biomarkers for validation in a subsequent clinical trial
- A57: T cell density and location can influence the prognosis of ovarian cancer
- A58: The Ovarian Cancer Tissue MicroArray Consortium
- A59: Development of a deuterium choline analogue radiotracer [18F]Fluoromethyl-[1,2-2H4]-choline for cancer imaging.
- A60: Androgen receptor expression in epithelial ovarian cancer decreases after exposure to chemotherapy: an immunohistochemical study
- A61: Fast and accurate method of microsatellite instability detection in FFPE tissue using high melting analysis (HRM)
- A62: MTBP as a prognostic indicator in squamous cell carcinoma of the head and neck (SCCHN)
- A63: Novel epigenetic biomarkers in the diagnosis of minimal residual disease in head and neck cancer (HNSCC)
- A64: Early stage pancreatic cancer protein biomarkers
- A65: Development of expression based biomarkers in NSCLC: a study of intratumour teterogeneity using FFPE tissue
- A66: Predicting the myelotoxicity of chemotherapy using O6-methylguanine-DNA methyltransferase
- A67: Proteomic profiling of prostate cancer progression by SELDI-TOF-MS
- A68: VORTEX-BIOBANK: translational tissue banking for the future individualisation of radiation treatment
- A69: HR23B: a biomarker for histone deacetylase inhibitor treatment in cutaneous T cell lymphoma
- A70: Can DNA repair proteins be used as molecular markers of survival in oesophageal cancer?
